Top Page
CK Life Sciences International (Holdings), Inc.
(0775)
CK Life Sciences International (Holdings), Inc. (0775) vs. iShares MSCI Hong Kong ETF (EWH)
CK Life Sciences International (Holdings), Inc. Business Overview & Revenue Model
CK Life Sciences International (Holdings), Inc. Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 5.52B | 5.32B | 5.28B | 5.40B | 4.94B |
| Gross Profit | 1.69B | 1.64B | 1.63B | 1.63B | 1.41B |
| EBITDA | 337.27M | 624.75M | 469.51M | 449.14M | 353.62M |
| Net Income | -126.55M | 17.25M | 131.96M | 162.80M | 125.23M |
Balance Sheet | |||||
| Total Assets | 10.79B | 11.25B | 11.27B | 11.73B | 11.98B |
| Cash, Cash Equivalents and Short-Term Investments | 571.21M | 676.16M | 704.13M | 902.47M | 971.71M |
| Total Debt | 6.10B | 5.93B | 5.95B | 6.21B | 6.19B |
| Total Liabilities | 7.28B | 7.06B | 7.11B | 7.23B | 7.26B |
| Stockholders Equity | 3.51B | 4.19B | 4.16B | 4.50B | 4.72B |
Cash Flow | |||||
| Free Cash Flow | 154.06M | 222.35M | 146.69M | 206.33M | 151.12M |
| Operating Cash Flow | 353.53M | 514.18M | 363.66M | 423.57M | 530.96M |
| Investing Cash Flow | -96.64M | -67.96M | -22.12M | -257.88M | -457.31M |
| Financing Cash Flow | -341.98M | -477.95M | -515.34M | -220.08M | 168.74M |
CK Life Sciences International (Holdings), Inc. Technical Analysis
CK Life Sciences International (Holdings), Inc. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | HK$8.36B | ― | -3.29% | ― | 3.76% | -833.33% | |
62 Neutral | HK$8.43B | 223.73 | 4.16% | ― | 34.39% | ― | |
59 Neutral | HK$15.36B | 5.63 | -7.44% | 4.08% | 11.55% | -28.15% | |
57 Neutral | HK$8.45B | ― | -13.97% | ― | -97.81% | -117.20% | |
55 Neutral | HK$7.31B | ― | -8.04% | ― | 66.72% | 33.68% | |
46 Neutral | HK$6.82B | 272.76 | 2.28% | ― | -57.55% | -87.49% |
CK Life Sciences International (Holdings), Inc. Corporate Events
CK Life Sciences International (Holdings) Inc. successfully conducted its Annual General Meeting on May 22, 2025, where all proposed resolutions were passed with overwhelming support. The resolutions included the approval of the audited financial statements for 2024, the election of directors, the appointment of auditors, and the granting of mandates to issue and buy back shares. This outcome reinforces the company’s governance structure and operational strategy, potentially strengthening its market position and shareholder confidence.
CK Life Sciences International (Holdings) Inc. has outlined the terms of reference for its Nomination Committee, which was established to ensure effective corporate governance in compliance with the Hong Kong Stock Exchange’s Listing Rules. The committee is responsible for reviewing the board’s structure and composition, identifying and recommending director candidates, assessing director independence, and supporting board performance evaluations. These measures are designed to align the board’s capabilities with the company’s strategic goals and enhance shareholder value.
CK Life Sciences International (Holdings) Inc. has outlined the terms of reference for its Audit Committee, which plays a crucial role in overseeing the company’s financial reporting, risk management, and internal control systems. The Audit Committee is composed of non-executive directors, with a majority being independent, and is tasked with ensuring compliance with corporate governance standards. This announcement underscores the company’s commitment to maintaining robust governance practices, which is vital for stakeholder confidence and the company’s operational integrity.
CK Life Sciences International (Holdings) Inc. announced its plans to present new data from preclinical studies of investigational cancer vaccines at the 2025 AACR Annual Meeting. The vaccines target proteins such as PRAME, PD-L1, B7-H3, and Claudin 6, which are associated with different cancers. The company is also making progress in developing an AI-powered platform to improve vaccine design. While the preclinical results are promising, the company has not yet commenced clinical trials, and stakeholders are advised to exercise caution.
CK Life Sciences International (Holdings) Inc. has announced its upcoming Annual General Meeting (AGM) scheduled for May 22, 2025, which will be held as a hybrid meeting both in-person and online. Key agenda items include the election of directors, appointment of auditors, and a resolution to grant the directors a mandate to issue additional shares, not exceeding ten percent of the current issued shares, with specific conditions on pricing and issuance period. This meeting is crucial for stakeholders as it will determine the company’s strategic directions and governance for the coming year.
CK Life Sciences International (Holdings) Inc. has announced promising preclinical results for its novel cancer vaccines targeting TROP2, a protein overexpressed in various aggressive cancers. The vaccines have shown impressive tumor growth inhibition in mice studies, particularly in breast and colorectal cancers, and the company aims to advance these vaccines into clinical trials. The potential commercialization of these vaccines could bring significant economic benefits, although clinical trials have not yet commenced, and patent approvals are pending.
CK Life Sciences International (Holdings), Inc. has announced a trading halt of its shares on the Hong Kong Stock Exchange as of April 10, 2025, pending a forthcoming announcement. This move indicates a significant development within the company, potentially impacting its market position and stakeholder interests.